Back to list

Diabetic Gastroparesis

University of North Carolina at Chapel Hill


Description

The purpose of this research study is to see if a new medication (Relamorelin) is effective for the management and treatment of Diabetic Gastroparesis. This is a Phase 3 Clinical Trial.


Keywords:

Diabetes, Stomach, Digestion


Category:

Drug or Biologic
Phase:3

Qualifications

 


Age
18 - 99 years


Gender
Any


Study Population

Adults, aged 18 and up suffering with current symptoms of Diabetic Gastroparesis (i.e. such as: nausea, abdominal pain, post-prandial fullness, bloating, vomiting, and early satiety).


Investigator

Spencer Dorn
Associate Professor
Medicine-Gastroenterology

For questions, contact:

Ariel Watts
Ariel_Watts@med.unc.edu
(919) 843-0821
Visit Website

Recruitment Period End

January 1, 2019

Location

Primary Location
Clinical & Translational Research Center
Burnett-Womack Building, 160 Dental Cir, Chapel Hill, NC 27514, USA

Study Qualifications

Gender Any

Age Range 18 - 99 years

Participant qualification(s) Documented diagnosis of Type 1 or Type 2 Diabetes and Diabetic Gastroparesis.

Not eligible if: Previous treatment of Relamorelin, or current participant in an investigational drug study.

Number of Visits

    » 7 In person visit(s)

    2 Screening, 1 Baseline, 4 Clinic OR 7 Clinic visits

    » 1 Remote visit(s)

    1 Telephone Screening Visit

Participation Period

16 Weeks

Compensation

Up to $875

By clicking I am interested, your contact information will be sent to the researcher/study coordinator for this study. The coordinator will respond by email with additional information on how to proceed.